Home › Squamous Cell Carcinoma ng Ulo at Leeg › Illinois
Pag-aaral pangklinika para sa Squamous Cell Carcinoma ng Ulo at Leeg sa Illinois
30 pag-aaral para sa Squamous Cell Carcinoma ng Ulo at Leeg ang naghahanap ng mga kalahok sa mga site sa Illinois.
Mga Lungsod sa Illinois
- Chicago26 pag-aaral
- Evanston8 pag-aaral
- Peoria7 pag-aaral
- Decatur7 pag-aaral
- Springfield6 pag-aaral
- Bloomington6 pag-aaral
- Charleston6 pag-aaral
- Danville6 pag-aaral
- Naperville6 pag-aaral
- Waukegan6 pag-aaral
- Champaign6 pag-aaral
- Cicero6 pag-aaral
- Joliet6 pag-aaral
- North Peoria5 pag-aaral
- Aurora5 pag-aaral
- Galesburg5 pag-aaral
- Elgin3 pag-aaral
- Arlington Heights3 pag-aaral
Opisyal na teksto ng pag-aaral (English)
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
- Rush-Copley Medical Center, Aurora
- Advocate Outpatient Center - Aurora, Aurora
- Advocate Good Shepherd Hospital, Barrington
- at 39 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06992427FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
- Captain James A Lovell Federal Health Care Center-VA North Chicago (Site # 133), Chicago
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06788990A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- University of Chicago Hospital, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT06465069Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
- Exelixis Clinical Site #26, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT05176483Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
- Advocate Good Shepherd Hospital, Barrington
- University of Chicago Comprehensive Cancer Center, Chicago
- Advocate Illinois Masonic Medical Center, Chicago
- at 29 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06589804BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Rush-Copley Medical Center, Aurora
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- at 38 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT05136196A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
- Rush University Medical Center Rush University Cancer Center Chicago, Chicago
- The University of Chicago Medical Center (UCMC), Chicago
- Cancer Care Specialists of Central Illinois, O'Fallon
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07276399A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- The University of Chicago Medical Center (UCMC), Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06385080Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- Northwestern University, Chicago
- John H Stroger Jr Hospital of Cook County, Chicago
- University of Illinois, Chicago
- at 14 pa
Nagre-recruitPhase 2
Edad 18 hanggang 79 · Lahat ng kasarian · Na-update Set 22, 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Northwestern University Feinberg School of Medicine, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 21, 2026 · NCT05983432A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
- City of Hope, Chicago, Zion
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07109726Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- OSF Saint Anthony's Health Center, Alton
- Rush-Copley Medical Center, Aurora
- Advocate Good Shepherd Hospital, Barrington
- at 53 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 14, 2026 · NCT02734537A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
- Northwestern University Feinberg School of Medicine, Chicago
- Cancer Care Specialists of Illinois, Decatur
- Illinois Cancer Care, Peoria
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Set 3, 2026 · NCT06163534A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Northwestern University, Evanston
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 21, 2026 · NCT06769698A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors
- University of Chicago Medical Center /ID# 276638, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 19, 2026 · NCT07241039Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer
- Northwestern University, Chicago
- Rush MD Anderson Cancer Center, Chicago
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT04333537Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- at 21 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT06532279Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin
- OSF Saint Joseph Medical Center, Bloomington
- Illinois CancerCare-Bloomington, Bloomington
- Illinois CancerCare-Canton, Canton
- at 22 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 17, 2026 · NCT07441681SMP-3124LP in Adults With Advanced Solid Tumors
- Northwestern Medicine Cancer Center, Chicago
- The University of Chicago, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT06526819A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Orchard Healthcare Research Inc, Skokie
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 5, 2026 · NCT06330064A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- Ingalls Family Care Center, Calumet City
- UChicago Medicine - River East, Chicago
- The University Of Chicago, Chicago
- at 13 pa
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT04389632A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
- The University of Chicago Medical Center - Oncology, Chicago
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 29, 2026 · NCT06747585Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago
- University of Chicago Medical Center /ID# 276271, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 23, 2026 · NCT05005403A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer
- University of Chicago Comprehensive Cancer Center, Chicago
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 12, 2026 · NCT05420948A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subjects With Oral and Lung Cancers
- The University of Chicago, Chicago
Nagre-recruitPhase 2/3
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Abr 23, 2026 · NCT05893888A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- University of Illinois Cancer Center, Chicago
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Abr 9, 2026 · NCT06064877Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
- The University of Chicago, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 4, 2026 · NCT05526924A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- The University of Chicago Comprehensive Cancer Center, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Peb 13, 2026 · NCT06778863A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
- Kellogg Cancer Center, Evanston
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Nob 4, 2025 · NCT05902988A Study of NX-1607 in Adults With Advanced Malignancies
- University of Chicago, Chicago
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 9, 2025 · NCT05107674Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.